Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1999 3
2001 1
2002 1
2004 1
2006 2
2007 1
2008 1
2010 1
2011 3
2012 2
2013 4
2014 1
2015 5
2016 4
2017 5
2018 3
2019 4
2021 1
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

43 results
Results by year
Filters applied: . Clear all
Page 1
PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor.
Xu H, Jesson MI, Seneviratne UI, Lin TH, Sharif MN, Xue L, Nguyen C, Everley RA, Trujillo JI, Johnson DS, Point GR, Thorarensen A, Kilty I, Telliez JB. Xu H, et al. Among authors: kilty i. ACS Chem Biol. 2019 Jun 21;14(6):1235-1242. doi: 10.1021/acschembio.9b00188. Epub 2019 May 22. ACS Chem Biol. 2019. PMID: 31082193
The Interleukin-1 Receptor-Associated Kinase 4 Inhibitor PF-06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial.
Winkler A, Sun W, De S, Jiao A, Sharif MN, Symanowicz PT, Athale S, Shin JH, Wang J, Jacobson BA, Ramsey SJ, Dower K, Andreyeva T, Liu H, Hegen M, Homer BL, Brodfuehrer J, Tilley M, Gilbert SA, Danto SI, Beebe JJ, Barnes BJ, Pascual V, Lin LL, Kilty I, Fleming M, Rao VR. Winkler A, et al. Among authors: kilty i. Arthritis Rheumatol. 2021 Dec;73(12):2206-2218. doi: 10.1002/art.41953. Epub 2021 Nov 1. Arthritis Rheumatol. 2021. PMID: 34423919 Clinical Trial.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects.
Danto SI, Shojaee N, Singh RSP, Li C, Gilbert SA, Manukyan Z, Kilty I. Danto SI, et al. Among authors: kilty i. Arthritis Res Ther. 2019 Dec 5;21(1):269. doi: 10.1186/s13075-019-2008-6. Arthritis Res Ther. 2019. PMID: 31805989 Free PMC article. Clinical Trial.
Antioxidant therapeutic targets in COPD.
Rahman I, Kilty I. Rahman I, et al. Among authors: kilty i. Curr Drug Targets. 2006 Jun;7(6):707-20. doi: 10.2174/138945006777435254. Curr Drug Targets. 2006. PMID: 16787173 Review.
JAK-STAT pathway activation in COPD.
Yew-Booth L, Birrell MA, Lau MS, Baker K, Jones V, Kilty I, Belvisi MG. Yew-Booth L, et al. Among authors: kilty i. Eur Respir J. 2015 Sep;46(3):843-5. doi: 10.1183/09031936.00228414. Epub 2015 Jun 25. Eur Respir J. 2015. PMID: 26113679 Free article. No abstract available.
TAK1 inhibition in the DFG-out conformation.
Kilty I, Green MP, Bell AS, Brown DG, Dodd PG, Hewson C, Hughes SJ, Phillips C, Ryckmans T, Smith RT, van Hoorn WP, Cohen P, Jones LH. Kilty I, et al. Chem Biol Drug Des. 2013 Nov;82(5):500-5. doi: 10.1111/cbdd.12169. Chem Biol Drug Des. 2013. PMID: 23745990
Opsonic Phagocytosis in Chronic Obstructive Pulmonary Disease Is Enhanced by Nrf2 Agonists.
Bewley MA, Budd RC, Ryan E, Cole J, Collini P, Marshall J, Kolsum U, Beech G, Emes RD, Tcherniaeva I, Berbers GAM, Walmsley SR, Donaldson G, Wedzicha JA, Kilty I, Rumsey W, Sanchez Y, Brightling CE, Donnelly LE, Barnes PJ, Singh D, Whyte MKB, Dockrell DH; COPDMAP. Bewley MA, et al. Among authors: kilty i. Am J Respir Crit Care Med. 2018 Sep 15;198(6):739-750. doi: 10.1164/rccm.201705-0903OC. Am J Respir Crit Care Med. 2018. PMID: 29547002 Free PMC article.
43 results